• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 5. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952

Introduction to 2-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethan-1-amine (CAS No. 2091582-15-7)

The compound 2-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethan-1-amine, identified by its CAS number 2091582-15-7, represents a significant advancement in the field of pharmaceutical chemistry. This heterocyclic amine derivative has garnered attention due to its structural complexity and potential therapeutic applications. The molecule features a fused pyrazole-pyrazine core, which is a hallmark of many bioactive scaffolds, suggesting a rich chemical space for further exploration.

Recent studies have highlighted the importance of dihydropyrazolo[1,5-a]pyrazine derivatives in medicinal chemistry. These compounds exhibit diverse biological activities, including anti-inflammatory, antiviral, and anticancer properties. The introduction of an amine group at the ethyl chain enhances the compound's pharmacological profile by potentially improving solubility and binding affinity to biological targets. This modification aligns with current trends in drug design, where optimizing molecular properties is crucial for achieving desired pharmacokinetic and pharmacodynamic outcomes.

The structural motif of 6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl is particularly noteworthy. It serves as a versatile scaffold that can be further functionalized to tailor specific biological activities. For instance, modifications at the 3-position of the pyrazole ring have been shown to modulate enzyme inhibition and receptor binding. Such structural flexibility makes this compound a valuable candidate for high-throughput screening and rational drug design initiatives.

In the context of contemporary pharmaceutical research, 2-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethan-1-amine (CAS No. 2091582-15-7) has been investigated for its potential role in addressing unmet medical needs. Preliminary in vitro studies indicate that this compound exhibits inhibitory effects on certain kinases and transcription factors implicated in chronic diseases. These findings are particularly relevant given the growing interest in kinase inhibitors as therapeutic agents.

The synthesis of this compound involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions and palladium-mediated transformations, have been employed to construct the complex heterocyclic framework efficiently. These synthetic strategies not only enhance the scalability of production but also allow for rapid diversification of the molecular library.

From a computational chemistry perspective, molecular modeling studies have been conducted to elucidate the binding interactions of 2-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethan-1-amine with target proteins. These simulations have provided insights into key pharmacophoric elements responsible for its observed biological activity. Such computational approaches are integral to modern drug discovery pipelines, enabling researchers to predict and optimize lead compounds before experimental validation.

The pharmacokinetic profile of this compound is another critical aspect under investigation. Studies suggest that modifications at the ethylamine moiety can significantly influence metabolic stability and distribution in vivo. Understanding these parameters is essential for translating preclinical findings into clinical efficacy. Furthermore, advances in biopharmaceutical analysis have facilitated the development of robust methods for characterizing drug-like properties early in the discovery process.

Collaborative efforts between academic institutions and pharmaceutical companies have accelerated the exploration of 2-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethan-1-amine (CAS No. 2091582-15-7). Such partnerships leverage complementary expertise in synthetic chemistry, medicinal chemistry, and bioinformatics to streamline drug development timelines. The integration of interdisciplinary approaches has become indispensable in addressing complex therapeutic challenges effectively.

The future prospects of this compound are promising, with ongoing research focusing on expanding its chemical diversity through structure-based drug design principles. By leveraging genomics and proteomics data, researchers aim to identify novel targets where this scaffold could exert therapeutic benefits. Additionally, green chemistry initiatives are being adopted to develop sustainable synthetic routes that minimize environmental impact while maintaining high chemical yields.

In conclusion,2-(6,7-dihydropyrazolo[1,5-a]pyrazin-5(4H)-yl)ethan-1-amine (CAS No. 2091582-15-7) stands as a testament to the ingenuity of modern pharmaceutical science. Its unique structural features and potential biological activities position it as a compelling candidate for further development into novel therapeutics. As research continues to uncover new applications for this compound, it will undoubtedly contribute significantly to advancements in human health care.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)